1774 related articles for article (PubMed ID: 26883132)
1. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
[TBL] [Abstract][Full Text] [Related]
8. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
[TBL] [Abstract][Full Text] [Related]
10. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Wang GH; Svensson M; Shao H; Vouri SM; Park H
J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
[No Abstract] [Full Text] [Related]
15. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS
Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.
Einarson TR; Pudas H; Zilbershtein R; Jensen R; Vicente C; Piwko C; Hemels ME
J Med Econ; 2013 Sep; 16(9):1096-105. PubMed ID: 23844621
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
Gozlan G; Lecardeur L; Monfort AS; Doz M; Ortiz I; Larroumets P; Lafuma A
Encephale; 2018 Dec; 44(6):496-503. PubMed ID: 30482480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
